NIVF Stock Analysis: Buy, Sell, or Hold?
NIVF - NewGenIvf Group Limited Class A ordinary shares
$1.06
-0.05 (-4.50%)
▼
5d:
-10.17%
30d:
+102.37%
90d:
+84.35%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Jun 30, 2026
0d
Get Alerted When NIVF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NIVF is down 10.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NIVF is down 10.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.37
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.16
89.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NIVF is currently trading at $1.06, which is considered extended relative to its 30-day fair value range of $0.44 to $1.00. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.0) compared to its historical average (0.1). Remarkably, the market is currently pricing in an annual earnings decline of 56.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NIVF is in a downtrend. Immediate support is located at $0.38, while resistance sits at $1.43. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: NIVF scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $127.08 (+11888.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NIVF is in a downtrend. Immediate support is located at $0.38, while resistance sits at $1.43. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: NIVF scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $127.08 (+11888.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.44 -
$1.00
Company Quality Score
29/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
19.0%
All Signals
- BEARISH: Price extended above range (+6.0% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.5%)
- BULLISH: Trading 11888.7% below Wall St target ($127.08)
- WARNING: Composite score 29/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.44 -
$1.00
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.38
Resistance Level
$1.43
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.01
Wall Street Target
$127.08
(+11888.7%)
Revenue Growth (YoY)
11.9%
Profit Margin
209.0%
Valuation Discount vs History
-56.9% cheaper
PE vs Historical
0.0 vs 0.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-56.9%
(market-implied from PE analysis)
1-Year Target
$0.95
(-10%)
2-Year Target
$0.86
(-19%)
3-Year Target
$0.77
(-27%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
$6.13
(+478%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 97.0%)
$5722.28
(+539738%)
Base:
(SPY PE: 0.0, Growth: 97.0%)
$3.58
(+238%)
Bear:
(PE: 0.0, Growth: 97.0%)
$3.04
(+187%)
📈
Valuation based on Current Earnings
Trailing PE: 0.00 | Current EPS (TTM): $328.32
Bull Case
$0.61
(-42%)
Analyst growth -50.0%, PE expands to 0.0
Base Case
$0.56
(-47%)
Market implied -50.0%, PE stable at 0.0
Bear Case
$0.76
(-28%)
Severe decline -20.0%, PE contracts to 0.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 0.0 to 0.1
Stabilization Target:
$8.41
(+693.0%)
PE Expansion Potential:
+693.0%
Share & Embed Analysis
Last updated: September 12, 2026 2:01 AM ET
Data refreshes hourly during market hours. Next update: 3:01 AM
Data refreshes hourly during market hours. Next update: 3:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NIVF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$285 | 61 BUY |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$451 | 50 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$148 | 55 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$24 | 52 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$135 | 56 HOLD |
